Carixa

Listed in the vendor table for B2B credit management and Chargeback management. Not named in any of the 168 answers those categories produced in the October 2026 Edition: fourteen models, six prompts per category and segment, every question asked three times, on behalf of a small B2B company, a mid-market B2B company and an enterprise B2B company, with every standing computed within one segment.

Standing

Not named in 168 answers

Absence in a measured set of answers is a finding, not a verdict: it says the models did not reach for Carixa when asked these questions this month. The products they named instead are listed by category below.

By buyer segment

The same categories asked on behalf of a different buyer. Each share and rank is computed within its segment; the columns sit side by side and are never added together.

Category	Small business	Mid-market	Enterprise
B2B credit management	not named	not named	0% · 28 of 80 1 label
Chargeback management	not named	not named	0% · 41 of 82 1 label

Where it was not named

Each category Carixa belongs to, the answers collected there, and who the models named first instead.

Category	Function	Named in	Named instead, first-choice share
B2B credit management	Receivables and billing	0 of 84	Chaser 16% · Tesorio 14% · Gaviti 12%
Chargeback management	Receivables and billing	0 of 84	Chargeflow 24% · Gaviti 12% · Midigator 10%

Is this your product?

Claim this page

Claiming is free and changes nothing in the data. A claimed page shows a verified contact who is told when each edition publishes and when Carixa's standing changes by more than the noise floor; the right to propose corrections to the vendor table, meaning names the judge wrote that should or should not read as Carixa, applied by version and listed in the change log; and a one-line description supplied by the vendor and marked as such.

What a new claim receivesHide what a new claim receives

A new claim receives the current edition's vendor brief for Carixa by email, built from the raw record of the edition. It shows:

where Carixa is named, by buyer and by framing, and which cells hold its first choices;
the claims the models make when they name it, ranked, with the strongest and the weakest quoted;
its vocabulary against the segment leader's, and the pages the models cited;
who was chosen in the answers that did not name Carixa, and every reason the record gives;
a battlecard for each top rival: the head-to-head split, why they win, and the reservation quoted against them;
one page of published figures cleared to show a buyer.